Eyeing Cancer Dx Market, ViroLogic to Buy Aclara Biosciences in $180M Deal | GenomeWeb

Late last summer, Bill Young, CEO of ViroLogic, asked Aclara Biosciences chief executive Tom Klopack to dinner to talk about what their companies could offer one another by way of commercial collaborations.

It must have been some meal.

Less than one year later, ViroLogic, eager to move into the growing cancer molecular diagnostics space, is betting that Aclara’s eTag technology — not to mention the company’s healthy bank balance — will help it grow beyond infectious disease testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.